# MRI-first prostate screening with genetic pre-selection

Source: https://onco.cc/ideas/idea-prev-mri-first-prostate-screening-prs/  
OnCo record `idea-prev-mri-first-prostate-screening-prs` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PSA screening finds harmless prostate cancers that would never cause trouble. Selecting men by PSA plus a polygenic risk score, then MRI before any biopsy and targeted biopsy only for PI-RADS 4 to 5 lesions, finds the dangerous cancers and skips the rest; GOTEBORG-2 showed MRI-targeted biopsy halves overdiagnosis.

## Summary

GOTEBORG-2 showed MRI-targeted biopsy halves overdiagnosis; BARCODE1 showed polygenic-score-selected men have high rates of clinically significant cancer. The UK TRANSFORM trial will compare pathways. Propose a national screening design combining PRS/PSA pre-selection, MRI, and targeted biopsy only for PI-RADS 4-5 lesions.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: The combined pathway detects clinically significant (Gleason 7 and above) cancer at rates similar to PSA screening while cutting Gleason 6 detection by at least half and biopsies by at least 40%.
- Rationale: Each component has randomised support; the combination is the programme design step.
- Proposed test: Embedded arm in TRANSFORM or a national pilot.
- Maturity: being-tested-at-scale
- Actor: policy

## Sources

- Prostate Cancer UK (TRANSFORM): https://prostatecanceruk.org

## Connected records

- roadmaps: [Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch](https://onco.cc/roadmaps/prostate-roadmap/)
- ideas: [Judge a prostate screening programme on metastatic presentation, not on incidence or mortality](https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/), [Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment](https://onco.cc/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Imaging](https://onco.cc/fronts/imaging/)
- technologies: [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/), [MRI](https://onco.cc/technologies/mri/)
- institutions: [The Institute of Cancer Research](https://onco.cc/institutions/icr-london/)
- terms: [PI-RADS (Prostate Imaging Reporting and Data System)](https://onco.cc/terms/pi-rads/), [Polygenic risk score (PRS)](https://onco.cc/terms/polygenic-risk-score/)
- bottlenecks: [Overdiagnosis and false alarms](https://onco.cc/bottlenecks/b-overdiagnosis/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- key papers: [Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction](https://onco.cc/key-papers/paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021/)

---
JSON: https://onco.cc/api/v1/entities/idea-prev-mri-first-prostate-screening-prs.json